相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong et al.
Journal of the National Comprehensive Cancer Network (2022)
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K. N. Moore et al.
ANNALS OF ONCOLOGY (2021)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer
Peter G. Rose et al.
ANTI-CANCER DRUGS (2021)
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard et al.
GYNECOLOGIC ONCOLOGY (2021)
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Ursula A. Matulonis et al.
CLINICAL CANCER RESEARCH (2019)
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
Michael J. Birrer et al.
ONCOLOGIST (2019)
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
Lainie P. Martin et al.
GYNECOLOGIC ONCOLOGY (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
Kathleen N. Moore et al.
CANCER (2017)
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments
Rajitha Lokadasan et al.
ECANCERMEDICALSCIENCE (2016)
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2015)
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
Olga Ab et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
Ilan Bruchim et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2013)
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
L. C. Hanker et al.
ANNALS OF ONCOLOGY (2012)
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Nicoletta Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
Yu-Li Chen et al.
MOLECULAR ONCOLOGY (2012)
Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube
Richard Wyn Griffiths et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
Ignace Vergote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 3 randomised study of canfosfamide (Telcyta (R), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
I. Vergote et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients
Eati Basal et al.
PLOS ONE (2009)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
Louis A. Dainty et al.
GYNECOLOGIC ONCOLOGY (2007)
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
N Parker et al.
ANALYTICAL BIOCHEMISTRY (2005)
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
M Gore et al.
EUROPEAN JOURNAL OF CANCER (2002)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
